Department of Biochemistry and Molecular Biology, The University of Chicago, Chicago, IL, USA.
Medicine Design, Worldwide Research and Development, Pfizer Inc., Eastern Point Road, Groton, CT, 06340, USA.
Nat Commun. 2020 Mar 27;11(1):1598. doi: 10.1038/s41467-020-15363-0.
We propose the concept of universal fiducials based on a set of pre-made semi-synthetic antibodies (sABs) generated by customized phage display selections against the fusion protein BRIL, an engineered variant of apocytochrome b562a. These sABs can bind to BRIL fused either into the loops or termini of different GPCRs, ion channels, receptors and transporters without disrupting their structure. A crystal structure of BRIL in complex with an affinity-matured sAB (BAG2) that bound to all systems tested delineates the footprint of interaction. Negative stain and cryoEM data of several examples of BRIL-membrane protein chimera highlight the effectiveness of the sABs as universal fiducial marks. Taken together with a cryoEM structure of sAB bound human nicotinic acetylcholine receptor, this work demonstrates that these anti-BRIL sABs can greatly enhance the particle properties leading to improved cryoEM outcomes, especially for challenging membrane proteins.
我们提出了基于一组预制半合成抗体(sAB)的通用标记概念,这些 sAB 是通过针对融合蛋白 BRIL(一种去细胞色素 b562a 的工程变体)的定制噬菌体展示选择产生的。这些 sAB 可以与融合到不同 GPCR、离子通道、受体和转运体的环或末端的 BRIL 结合,而不会破坏其结构。BRIL 与亲和力成熟的 sAB(BAG2)复合物的晶体结构与所有测试系统结合,描绘了相互作用的足迹。BRIL-膜蛋白嵌合体的几个实例的负染色和 cryoEM 数据突出了 sAB 作为通用标记的有效性。与结合人烟碱型乙酰胆碱受体的 sAB 的 cryoEM 结构一起,这项工作表明,这些抗 BRIL sAB 可以极大地增强颗粒特性,从而改善 cryoEM 结果,特别是对于具有挑战性的膜蛋白。